Dermira‘s Lebrikizumab Receives the US FDA’s Fast Track Designation to Treat Atopic Dermatitis

 Dermira‘s Lebrikizumab Receives the US FDA’s Fast Track Designation to Treat Atopic Dermatitis

Dermia‘s Lebrikizumab Receives the US FDA’s Fast Track Designation to Treat Atopic Dermatitis

Shots:                                                                                                              

  • The US FDA has granted Dermia’s Lebrikizumab Fast Track Designation an investigational drug targeted to treat moderate-to-severe atopic dermatitis
  • The Fast Track Designation is granted to facilitate the drug development process and expedite the review of therapies treating serious conditions and demonstrating an advantage over currently available therapy
  • Lebrikizumab is a mAb designed to bind to IL-13 further preventing the formation of the IL-13Rα1/IL-4Rα heterodimer complex and subsequent signaling currently evaluated in two P-III trial for, ADvocate 1 and Advocate 2 confirming safety, efficacy, in adolescent and adult patients, ages 12 years and older, with moderate-to-severe atopic dermatitis

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post